Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neovac 2 Burkina Faso: Hepatitis B Birth Dose Vaccine
NCT04029454Completed
- Sponsor
- Institut Pasteur
- Start
- Oct 2020
- Primary completion
- Aug 2023
- Modality
- Split/Subunit Vaccines, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Randomised, open-label trial of Hepatitis B vaccine in hepatitis B (HBV) (2 arms), sponsored by Institut Pasteur. Primary endpoint: Proportion of positive HBV infection (HBsAg) in 9-month-old children. Started Oct 2020; status: completed.
02
Drugs
Hepatitis B vaccine
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT04029454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04029454.